Outlaw Garage is a channel for car lovers who live for classic builds, rare finds, and timeless Porsches. Based in Australia, ...

Discover innovative cafes and a Michelin guide debut. Sacramento's Rice Theory offers tasty rice-based snacks, while Buenos Aires Grill brings Argentine flavors ...

Analysts are not writing off technology player Inari Amertron Bhd whose share price has dwindled of late, given the expected ...

CAMBRIDGE, Mass., April 3, 2025 /PRNewswire/ -- Inari, the SEEDesign™ company, has named Dr. Vivien Bonazzi chief data officer, effective April 1. A leading biomedical data scientist, Bonazzi is ...

In the 1990s, fewer than 350 people spoke Inari Sámi. Today, experts say about 500 people speak the near-extinct language, and the movement to learn it is growing.

Portage, Michigan, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today that it has completed the acquisition of Inari Medical, Inc ...

Inari is currently the 10th largest medical device company in Orange County with 678 employees as of last April. Employees that own any of Inari’s stock will have their shares converted to $80 per ...

Inari’s prime competitor is Penumbra, Inc. , and while Penumbra has roughly 50% share in the DVT market, Inari has been the stronger player in PE, with better than 70% share.

Medical device maker Inari Medical (NARI) may not be a readily-recognized name, but it is about to be part of a much bigger, and probably more recognizable, name: Stryker. Stryker agreed to buy ...

Inari Shares Rose 30% Monday, Over 20% Tuesday Morning . The deal was first reported to be near completion by Reuters Monday afternoon, and that news sent Inari stock just over 30% higher to $65 ...

Inari Medical recently reported a record Q3 revenue of $153.4 million, marking a 21% year-over-year increase, and raised its full-year revenue outlook to between $601.5 million and $604.5 million.

Medical-device maker Stryker on Monday agreed to acquire Inari Medical , which makes devices that treat patients with venous diseases, in an all-cash deal worth $4.9 billion.